

出國報告（出國類別：開會）

2022 聖安東尼奧乳癌研討會

服務機關：台中榮民總醫院
姓名職稱：劉佳樺 / 住院醫師
派赴國家/地區：美國/聖安東尼奧
出國期間：2022/12/04-2022/12/12
報告日期：2022/01/05

目 次

摘要	8
目的	9
過程	9-12
心得	12
建議	12-13
附錄	13

摘要

1. 會議簡介：創立於 1977，聖安東尼奧乳癌研討會（SABCS）現已踏入第 45 年，是基礎、轉化和臨床癌症研究專業人員的首要會議。
2. 會議內容：
 1. Education Session、General Session 和附加研討會（open satellite session），提供各類醫療人員，臨床問題討論的平台。
 2. 經審核的研究論文，依突破性和重要性高低分為三種類型發表：口頭發表(oral presentation)、亮點會議海報暨口頭簡報(Spotlight Poster Discussion Session Poster Presentation)以及海報發表(Poster Presentation)。此次參與海報發表。
 3. 展覽：各家醫療廠商，以攤位的方式展示新的手術器械和藥物，讓大家了解目前相關領域工具的進步，也讓有興趣的醫師在現場聆聽介紹或是實際使用。

關鍵字：乳癌、海報發表

一、目的

1. 投稿並參與國際會議，與國內外相關領域學者交流。
2. 獲取最新乳癌相關研究新知與方向，應用於臨床治療，亦可對撰寫論文或臨床試驗有新的發想。

二、過程

Education Session、General Session: 充實的會議內容、與會者間的交流提問

TUESDAY, DECEMBER 6 SCHEDULE-AT-A-GLANCE

*As of November 18, 2022 | **All times are CENTRAL Time

8:00 am – 9:45 am CT

Clinical Research Workshop
Stars at Night Ballroom 1&2

Basic Science Workshop
Stars at Night Ballroom 3&4

10:00 am – 12:00 pm CT

**EDUCATIONAL SESSION
BLOCK #1**

**Living with Metastatic Breast
Cancer**
Stars at Night Ballroom 3&4

**Local Therapy – Best Breast
Practice**
Hemisfair Ballroom 1&2

**New Agents Targeting HRD in
Breast Cancer**
Hemisfair Ballroom 3

**Predictive Value of Treatment
Response and Residual
Disease After Neoadjuvant
Therapy**
Stars at Night Ballroom 1&2

12:00 pm – 2:00 pm CT

SPECIAL SESSION:
Big Data and Health Equity
Stars at Night Ballroom 1&2

**Overcoming the Big Obstacles
to Find Solutions for Breast
Cancer**
Hall 3

2:00 pm – 5:00 pm CT

GENERAL SESSION #1
Hall 3

5:00 pm – 6:15 pm CT

POSTER SESSION #1
Hall 1

**SPOTLIGHT POSTER
DISCUSSION SESSION #1:**
Racial Outcomes and Disparities
Hemisfair Ballroom 1&2

**SPOTLIGHT POSTER
DISCUSSION SESSION #2:**
**Tumor Immunology and Novel
Immune Therapy Strategies**
Stars at Night Ballroom 1&2

**SPOTLIGHT POSTER
DISCUSSION SESSION #3:**
New Radiation Techniques
Stars at Night Ballroom 3&4

7:00 pm – 10:00 pm CT

Open Satellite Events

WEDNESDAY, DECEMBER 7 SCHEDULE-AT-A-GLANCE

*As of November 18, 2022 | **All times are CENTRAL Time

7:00 am – 8:15 am CT

POSTER SESSION #2
Hall 1

**SPOTLIGHT POSTER
DISCUSSION SESSION #4:**
**Single Cell Approaches
for Translational
Research and Biomarker
Discovery**
Hemisfair Ballroom 1&2

**SPOTLIGHT POSTER
DISCUSSION SESSION #5:**
**Advances in TNBC
Biology**
Stars at Night Ballroom
3&4

**SPOTLIGHT POSTER
DISCUSSION SESSION #6:**
**Special Populations:
Male Breast Cancer/
Geriatrics**
Stars at Night Ballroom
1&2

8:30 am – 9:00 am CT

**William L. McGuire
Memorial Lecture:
Leveraging Preclinical
Models for Translational
Breast Cancer Research**
Jeffrey Rosen, PhD
Hall 3

9:00 am – 9:45 am CT

GENERAL SESSION #2
Hall 3

9:45 am – 11:00 am CT

**HER2 Low: A Separate
Entity Special Session**
Hall 3

10:00 am – 5:00 pm CT

EXHIBITS
Hall 2

11:00 am – 12:00 pm CT

**Mini-Symposium: C.
Kent Osborne HER2
Signaling the ER Cistrome
Symposium**
Hall 3

12:00 pm – 12:30 pm CT

**Plenary Lecture: Lineage-
defined Metabolism of
Normal Mammary Cells
and Origins of Cancer
Metabolic Heterogeneity**
Rama Khokha, PhD
Hall 3

12:30 pm – 1:00 pm CT

**AACR Distinguished
Lectureship in Breast
Cancer Research**
Hall 3

12:30 pm – 1:30 pm CT

Career Development Forum
Room 304

1:00 pm – 2:00 pm CT

**FORUM: Molecular As-
pects of DCIS Progression**
Stars at Night Ballroom 3&4

**Clinical Case Discussion
Session**
Stars at Night Ballroom
1&2

2:00 pm – 3:00 pm CT

Clinical Controversies
Hall 3

**Mini-Symposium: Late
Recurrence and Tumor
Dormancy**
Stars at Night Ballroom
1&2

**Forum: New Targets
and Strategies for
Immunotherapy**
Stars at Night Ballroom 3&4

3:00 pm – 5:00 pm CT

**EDUCATIONAL SESSION
BLOCK #2**
**Digital Health and
PROs in Breast Cancer
Research and Care**
Hemisfair Ballroom 1&2

**Antibody Drug Conju-
gates: Future Directions
and Opportunities**
Stars at Night Ballroom
1&2

**Spatial and Single
Cell Characterization
of Breast Cancer
Progression**
Stars at Night Ballroom
3&4

**Breast Cancer and
Cardiovascular Toxicity:
What an Oncologist
Needs to Know**
Hemisfair Ballroom 3

5:00 pm – 6:15 pm CT

POSTER SESSION #3
Hall 1

**SPOTLIGHT POSTER
DISCUSSION SESSION #7:**
Brain Metastasis
Stars at Night Ballroom
3&4

**SPOTLIGHT POSTER
DISCUSSION SESSION #8:**
**Symptom Management
and Associate Toxicities**
Stars at Night Ballroom
1&2

**SPOTLIGHT POSTER
DISCUSSION SESSION #9:**
**Immune Landscape and
Microenvironments**
Hemisfair Ballroom 1&2

7:00 pm – 10:00 pm CT

**OPEN SATELLITE
EVENTS**
Marriott Rivercenter

THURSDAY, DECEMBER 8 SCHEDULE-AT-A-GLANCE

*As of November 18, 2022 | **All times are CENTRAL Time

7:00 am – 8:15 am CT

POSTER SESSION 4

Hall 1

**SPOTLIGHT POSTER
DISCUSSION**

SESSION #10:

Endocrine Therapy and
Resistance

Stars at Night Ballroom 3&4

**SPOTLIGHT POSTER
DISCUSSION**

SESSION #11:

Improving Outcome for
TNBC: New Directions in
Immunotherapy

Stars at Night Ballroom 1&2

**SPOTLIGHT POSTER
DISCUSSION**

SESSION #12:

Obesity and Breast Cancer

Hemisfair Ballroom 1&2

8:30 am – 11:00 am CT

GENERAL SESSION #3

Hall 3

10:00 am – 5:00 pm CT

EXHIBITS

Hall 2

11:00 am – 12:00 pm CT

Debate: Are All of CDK4/6
Inhibitors the Same or Different?

Hall 3

12:00 pm – 12:30 pm CT

Plenary Lecture: Premenopausal
ER+ Breast Cancer: Past,
Present, and Future
Prudence Francis, MD

Hall 3

12:30 pm – 1:00 pm CT

Brinker Award for Scientific
Distinction in Basic Science
Lecture

Geoffrey M. Wahl, PhD

Hall 3

1:00 pm – 2:00 pm CT

Molecular Tumor Board

Stars at Night Ballroom 1&2

Forum: Modifying Tumor Response:
Microbiome, Diet, and Fasting

Stars at Night Ballroom 3&4

2:00 pm – 3:00 pm CT

Translational Controversies

Stars at Night Ballroom 1&2

Forum: Demystifying CDKs In
Breast Cancer: Beyond CDK4/6

Stars at Night Ballroom 3&4

3:00 pm – 5:00 pm CT

EDUCATIONAL SESSION BLOCK #3
Management of Hereditary Risk:
Moderate-Risk Genes and New
Approaches

Hemisfair Ballroom 1&2

Challenging Types of Breast Cancer

Stars at Night Ballroom 1&2

What ctDNA Can Tell Us

Stars at Night Ballroom 3&4

5:00 pm – 6:15 pm CT

POSTER SESSION #5

Hall 1

**SPOTLIGHT POSTER
DISCUSSION SESSION #13**
Therapeutic Approaches for
HR+/HER2- Breast Cancer

Stars at Night Ballroom 1&2

**SPOTLIGHT POSTER
DISCUSSION SESSION #14**
Breast Cancer Risk Modeling

Stars at Night Ballroom 3&4

**SPOTLIGHT POSTER
DISCUSSION SESSION #15:**
Local Regional/Management of
the Axilla

Hemisfair Ballroom 1&2

7:00 pm – 10:00 pm CT

OPEN SATELLITE EVENTS
Marriott Rivercenter

FRIDAY & SATURDAY, DECEMBER 9–10 SCHEDULE-AT-A-GLANCE

*As of November 18, 2022 | **All times are CENTRAL Time

FRIDAY, DECEMBER 9

7:00 am – 8:15 am CT

POSTER SESSION #6

Hall 1

**SPOTLIGHT POSTER
DISCUSSION SESSION
#16:**

Imaging to Diagnose
Breast Cancer and Direct
Its Treatment: Who,
When, and How?

Hemisfair Ballroom

**SPOTLIGHT POSTER
DISCUSSION SESSION
#17**

Endocrine Therapy New
Insights

Stars at Night Ballroom 1&2

**SPOTLIGHT POSTER
DISCUSSION SESSION
#18**

Updates and New
Therapies for HER2
Positive Disease

Stars at Night Ballroom 3&4

8:30 am – 9:00 am CT

AACR Outstanding
Investigator Award for
Breast Cancer Research

Hall 3

9:00 am – 11:30 am CT

GENERAL SESSION #4

Hall 3

10:00 am – 5:00 pm CT

EXHIBITS

Hall 2

11:30 am – 12:00 pm CT

Brinker Award for Sci-
entific Distinction in
Clinical Research
Norman Wolmark, MD,
FACS, FRCSC

Hall 3

12:00 pm – 3:00 pm CT

GENERAL SESSION #5

Hall 3

3:00 pm – 5:00 pm CT

**EDUCATIONAL SESSION
BLOCK #4**
Advances in Pregnancy
Associated Breast
Cancer (PABC)

Stars at Night Ballroom 1&2

State of the Art
Radiotherapy: Reducing
Toxicity and Increasing
Options

Stars at Night Ballroom 3&4

Targeting the Tumor
Microenvironment for
Clinical Impact

Hemisfair Ballroom 1&2

5:00 pm – 5:15 pm CT

Refreshment Break

5:15 pm – 7:15 pm CT

View from the Trenches:
What will You do on
Monday Morning?

Stars at Night Ballroom 1&2

**SATURDAY,
DECEMBER 10**

8:00 am – 10:00 am CT

The Year In Review

Hall 3

10:00 am CT

Meeting Adjourns



海報發表(Poster Presentation)

Endometriosis, Risk, and
Management in
Postmenopausal Women
P3-03-26

Osteopenia and osteoporosis in women with breast cancer in Taiwan: a single center retrospective data

Chia-Hua Du*, Chin-Chiang Hong*, I-Chen Tsai*, Chiann-Yi Hsu*

*Tainan General Hospital, Tainan, Taiwan; *National Taiwan University Hospital, Taipei, Taiwan; *National Taiwan University Hospital, Taipei, Taiwan; *National Taiwan University Hospital, Taipei, Taiwan

INTRODUCTION

- Osteopenia and osteoporosis are prevalent in older women. One third of women older than fifty years old suffer a broken bone due to osteoporosis around the world.
- Treatments for breast cancer such as chemotherapy or hormonal therapy increase the risk of osteoporosis.
- Trabecular bone score (TBS), an index extracted by DXA that provides an indirect measurement of axial bone micro-architecture, which may predict fracture risk at the individual level.
- TBS values <1.30 is considered normal in postmenopausal women, but there is limited data for breast cancer population.

PATIENT POPULATION

- A total of 201 female who diagnosed with breast cancer between May 2019 and December 2020.
- Patients with bone metastasis (n=11) and double cancer (n=3) were excluded.
- All 187 patients have accepted dual energy X-ray absorptiometry (DXA) at least once, including Bone mineral density (BMD), T-score (spine and total hip) and Trabecular Bone Score (TBS) data.

STUDY METHODS

- Charts were retrospectively analyzed baseline age, BMD, breast cancer subtype, Aromatase Inhibitors (AI) use by Kruskal-Wallis test and Chi-Square test.
- 50 females without cancer were retrospectively collected, matched with breast cancer group through <1.1 age- and BMI matching. Differences between the cases and controls were determined using Mann-Whitney U test.

RESULTS

- 58.2% (n=109) of osteopenia ($-2.5 < T < -1$) and 27.8% (n=52) of osteoporosis ($T < -2.5$) were identified in women with breast cancer.
- Forty percent of TNBC patients diagnosed osteoporosis. There was no difference in BMD according to breast cancer subtype (table 1).
- Patients who used AI (n=80) had lower BMD and TBS than non-AI group (n=97) (table 2).
- T-score is significant higher in non-cancer group, but the TBS was better in cancer group (table 3).

	Normal group (n=76)	Osteopenia group (n=109)	Osteoporosis group (n=52)	p-value
Age (mean±SD)	52.35 (±8.5)	54.48 (±9.1)	60.1 (±10.1)	0.001**
BMI (mean±SD)	24.07 (±2.95)	24.76 (±3.77)	23.07 (±1.28)	0.025*
Molecular subtype				0.9
Luminal type (n=146)	19 (13%)	87 (60%)	40 (27%)	
HER2-enrich type (n=31)	4 (13%)	19 (61%)	8 (26%)	
TNBC (n=10)	3 (20%)	4 (40%)	4 (40%)	

	Non-AI (n=97)	AI (n=80)
Age	52.75 ±9.89	58.96 ±8.96
TBS	1.15 ±0.10	1.30 ±0.09
T-score	-1.84 ±0.87	-2.19 ±0.87

	Breast cancer (n=187)	Non-cancer (n=161)	p-value
Age	55.74 ±9.93	55.78 ±10.81	0.724
BMI	24.20 ±3.59	24.12 ±4.25	0.584
T-score	-2.01 ±0.89	-1.77 ±1.15	0.079*
TBS	1.32 ±0.10	1.30 ±0.11	0.015*

CONCLUSION

- AI group had lower BMD and TBS than non-AI group (p<0.05), which corresponded to past researches.
- Clinicians should be aware of osteoporosis in chemotherapy-induced premature ovarian failure patients.
- In our study, mean TBS in breast cancer group is 1.32 and 1.3 in non-cancer group. Further research is needed to determine the validity of cut-points for guiding treatment decisions.

展覽：各家醫療廠商，以攤位的方式展示新的手術器械和藥物



三、心得

以前總把國際會議想得離自己很遙遠，覺得要大型、很有突破性的研究才沾得上邊。這次在洪主任的鼓勵下，將曾投稿過外科年會的題目，加上新的數據後投稿，竟有幸被挑選發表。與之前在國內的海報發表不同，除了電子海報，也需製作實體海報至現場張貼，並在旁即時解說，對我而言是一大挑戰。從如何把實體海報設計得清楚明瞭、模擬可能被問的問題、如何應對等等，整個過程都是全新的體驗。

在展覽中看到新的手術器械，細問之下，發現大都還未進入亞洲市場，有進亞洲的則多在日本和新加坡，雖在現場有與業務交換聯絡方式，但後續收到的回覆是：近期沒有進入台灣市場的計劃。頗為遺憾。

四、 建議

1. 參加國外的研討會，有助於住院醫師在學習、研究等方面的成長，與國內外相關領域學者交流，獲取最新乳癌相關研究新知與方向，應用於臨床治療，亦可對撰寫論文或臨床試驗有新的發想。可多推廣醫師出國學習
2. 大型國際會議，與會者幾乎都是歐美人士，不論是學術上的交流、日常的閒聊，讓我再次感受到語言的重要。建議可開設如何口頭發表論文的相關課程。
3. 會議上看到許多大型、小型的臨床試驗。住院醫師開始寫論文，都是從 case report 或是 retrospective study 為主，對 clinical trial 比較陌生。建議可開設相關教學課程，從 IRB 的撰寫、醫院有何可利用的臨床數據、如何建立(或加入) clinical trial。可減少自己摸索的時間。
4. 在展場看到可以偵測腫瘤邊緣是否切除乾淨的機器 (Lumicell)，在美國已有許多 clinical trial，現獲 FDA「快速審查認定」(Fast Track Designation)之開發案，並獲得滾動式審查的資格(Rolling Review)。建議能追蹤此機器的審核後續，評估是否能引進台灣。

五、 附錄 (與會證明)

